Written and maintained by CASRAI Editorial Board
Last updated
General standards and regulatory information for laboratory and clinic staff. It is not medical advice and not a test protocol.
Short answer
ISO 10993-6, “Biological evaluation of medical devices, Part 6: Tests for local effects after implantation”, sets requirements for implantation test methods used in the preclinical assessment of local tissue effects. The current edition is ISO 10993-6:2026, valid from 15 April 2026; it follows ISO 10993-6:2016. It does not evaluate mechanical or functional performance, and it does not give guidance on systemic toxicity, carcinogenicity, teratogenicity or mutagenicity.
Definition and scope
Part 6 belongs to the ISO 10993 series on the biological evaluation of medical devices. Its listed scope is implantation test methods for the preclinical assessment of local effects. It applies to devices used where skin or mucosal tissue is breached, and to solid and non-solid materials, absorbable and non-absorbable materials, and tissue-engineered medical products. The search variant “iso 10993 6” refers to the same document.
Other parts of the series cover other endpoints. For example, see our guides on ISO 10993-4 (interactions with blood), ISO 10993-11 (systemic toxicity) and ISO 10993-12 (sample preparation). For the framework that decides which endpoints a device needs, see FDA guidance on biocompatibility and ISO 10993.
What ISO 10993-6 covers and what it does not
| Question | Within Part 6 | Source |
|---|---|---|
| Local tissue effects after implantation | Yes, this is the subject of the document | EVS listing of ISO 10993-6:2026 |
| Mechanical or functional performance of the device | No | EVS listing |
| Systemic toxicity, carcinogenicity, teratogenicity, mutagenicity | No guidance given; study designs may be adapted to assess other effects | EVS listing |
| Absorbable and non-absorbable materials, tissue-engineered products | Both are in scope | EVS listing |
The full test requirements are in the purchased standard. This guide does not reproduce them.
How FDA uses Part 6
FDA’s guidance on the use of ISO 10993-1 (nonbinding recommendations) refers to ISO 10993-6 in its section on implantation. Four points from that section matter when reading a supplier’s report.
Clinically relevant implantation versus muscle or subcutaneous implantation
FDA states that, instead of a traditional toxicology implantation study in subcutaneous, muscle or bone tissue, a clinically relevant implantation assessment (for example brain or vascular) may be more appropriate for certain implant devices with relatively high safety risks, as described in ISO 10993-6. FDA describes clinically relevant studies as critical for determining the systemic and local tissue responses to the implant in a relevant anatomical environment under simulated clinical conditions.
The muscle study as a supplemental test
FDA notes that muscle or subcutaneous implantation is often not needed when clinically relevant studies have been done, but may help as a screening test for local toxicity. It cautions that muscle implants form a fibrous capsule that can contain eluted material and give an exaggerated response, and that a muscle study should be considered a supplemental test, especially with new materials or chemicals or when the clinically relevant study raises toxicity concerns.
Coupons and sub-components
FDA says coupons or sub-components may be acceptable instead of the final finished device when geometry confounds interpretation, with justification. Its example is a coupon in place of a stent when surface properties are shown to be comparable.
Degradable materials
For degradable materials FDA recommends interim assessments: with minimal or no degradation, during progressive degradation, and once degradation and tissue response reach a steady state. Time points may be based on in vitro degradation testing.
Where it matters for labs, clinics and supply decisions
A supplier’s implantation report is one part of a wider biocompatibility file. The checklist below turns the points above into questions to put to a supplier. Each row traces to the sources listed at the end; none is a rule from the standard itself.
| Ask for | Why it follows from the sources |
|---|---|
| Which edition of ISO 10993-6 the report cites (2016 or 2026) | Two editions exist; the 2026 edition is valid from 15 April 2026 |
| Whether the test article was the finished device or a coupon, and the justification | FDA accepts coupons or sub-components only with justification |
| The implantation site and the reason it was chosen | FDA distinguishes clinically relevant sites from muscle, subcutaneous or bone tissue |
| For muscle or subcutaneous studies, whether they were used as a supplement or screen | FDA treats the muscle study as supplemental and notes the fibrous-capsule caveat |
| For degradable materials, the interim time points used | FDA recommends interim assessments through to steady state |
| The biological evaluation plan that placed implantation among the endpoints | Implantation is one endpoint in the FDA evaluation framework; see FDA guidance on biocompatibility |
| The supplier’s quality management system certification | See ISO 13485 for what that standard covers |
Common misunderstandings
- Part 6 is not the whole of ISO 10993. It covers local effects after implantation. Systemic toxicity sits in Part 11, and the listing says Part 6 gives no guidance on it.
- Part 6 is not a performance test. It does not evaluate mechanical or functional performance.
- A muscle implantation study does not replace a clinically relevant one. FDA frames muscle implantation as supplemental or screening, with a fibrous-capsule caveat.
- The 2016 edition is not the only edition. A report that cites 2016 predates the 2026 edition’s validity date.
FAQ
Is ISO 10993-6 the same as ISO 10993-1?
No. Part 1 is the evaluation framework that FDA’s guidance addresses; Part 6 is one test-method part, for local effects after implantation.
Does ISO 10993-6 test systemic toxicity?
No. The listed scope says it gives no guidance on systemic toxicity, carcinogenicity, teratogenicity or mutagenicity, although study designs may be adapted to assess other effects. Systemic toxicity is the subject of ISO 10993-11.
Which edition is current?
ISO 10993-6:2026, valid from 15 April 2026. The earlier version is ISO 10993-6:2016 (28 November 2016).
What is “iso 10993 6”?
The same standard, written without the hyphen.
Sources
- EVS (Estonian Centre for Standardisation and Accreditation), listing for ISO 10993-6:2026, evs.ee/en/iso-10993-6-2026, date checked 2026-11-01.
- U.S. FDA, “Use of International Standard ISO 10993-1, Biological evaluation of medical devices”, guidance document, section on implantation, fda.gov/media/142959/download, date checked 2026-11-01. Nonbinding recommendations.
